Evolus/$EOLS
1D1W1MYTD1Y5YMAX
Capital at risk
About Evolus
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Ticker
- $EOLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 353
- Headquarters
- Newport Beach, United States
- Website
- www.evolus.com
Evolus Metrics
BasicAdvanced
$528M
-
-$0.53
1.36
-
Price and volume
Market cap
$528M
Beta
1.36
52-week high
$9.31
52-week low
$3.86
Average daily volume
1.1M
Financial strength
Current ratio
1.697
Quick ratio
1.089
Long term debt to equity
-5.072
Total debt to equity
-5.333
Interest coverage (TTM)
-1.34%
Profitability
EBITDA (TTM)
-12.774
Gross margin (TTM)
66.40%
Net profit margin (TTM)
-10.85%
Operating margin (TTM)
-6.84%
Effective tax rate (TTM)
-1.94%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
-5.68%
Return on equity (TTM)
138.57%
Valuation
Price to revenue (TTM)
1.646
Price to book
-17.07
Price to tangible book (TTM)
-17.07
Price to free cash flow (TTM)
-20.015
Free cash flow yield (TTM)
-5.00%
Free cash flow per share (TTM)
-0.399
Growth
Revenue change (TTM)
13.87%
Earnings per share change (TTM)
-45.89%
3-year revenue growth (CAGR)
23.35%
3-year earnings per share growth (CAGR)
-23.54%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Analyst projections of the future price of Evolus stock.
Bulls say / Bears say
Total net revenues for Q2 2026 rose 21% year-over-year to $84.1 million, driven by double-digit growth in Jeuveau and accelerating adoption of Evolysse, underscoring strong top-line momentum. (Businesswire)
Evolus raised its full-year 2026 revenue guidance to $330 million–$337 million and increased adjusted gross profit margin guidance to 67.0%–67.5%, reflecting management’s confidence in maintaining growth and improving profitability. (Businesswire)
The company reported a third consecutive quarter of positive adjusted EBITDA ($4.7 million in Q2 2026), highlighting improving operating leverage and a clear path toward sustained profitability. (Businesswire)
Evolysse product revenue in Q2 2026 declined to $8.9 million from $9.7 million in Q2 2025, indicating potential challenges in the adoption of its HA gel portfolio. (SEC)
GAAP operating loss of $4.5 million in Q2 2026 alongside $61.7 million in operating expenses underscores persistent unprofitability despite adjusted EBITDA gains. (Businesswire)
Full-year 2026 guidance assumes no revenue contribution from the anticipated U.S. approval of Evolysse Sculpt in Q4 2026, delaying potential growth from its next-generation HA gel offering. (Businesswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evolus News
AllArticlesVideos
Evolus Q2 Earnings Call Highlights
MarketBeat1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 months ago
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Business Wire2 months ago
Funds containing Evolus
AllUSDGBPEUR
Fund name | Fund size | $EOLS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.